In vitro investigation of RGD-modified stabilized cationic liposomes as non-viral vehicle for siRNA delivery

Abstract

Abstract:

In this study, the novel RGD-modified stabilized cationic liposomes were developed as the delivery vehicle for siRNA targeting human MDR1 gene. The complex of cationic liposomes and siRNA, RGD-Lipo-siRNA, was prepared with a narrow size distribution below 200 nm. It was shown that the encapsulated siRNA in the liposomes could be effectively protected from serum degradation. Also, enhanced cell binding and intracellular uptake of siRNA in the doxorubicin-resistant human ovarian cancer cell lines SKOV3/A were found in RGD-Lipo-siRNA preparation as compared to that of unmodified cationic lipsomes (Lipo-siRNA). Using the post-insertion method for RGD modification, lysosome release of siRNA in pRGD-Lipo-siRNA was improved. From flow cytometry, significant increase of doxorubicin accumulation was observed in the SKOV3/A cells treated with pRGD-Lipo-siRNA targeting human MDR1 gene. In vitro cytotoxicity assay showed that the significant cell growth inhibition was achieved in the SKOV3/A cells after treating with the combined use of siRNA and doxorubicin. In conclusions, postinserted RGD modified lipoplex, pRGD-Lipo-siRNA, was successfully used for siRNA transfection and achieved drug resistance reversal in human ovarian cancer SKOV3/A (doxorubicin-resistant) cells. It suggested that this liposomes might be a potential vehicle for siRNA delivery in vivo.

Key words: siRNA, siRNA, Cationic liposomes, Cationic liposomes, DC-Chol, DC-Chol, RGD modification, RGD modification, ,

CLC Number:

R943.42

Supporting:

Shi-Jin Yang, Li-Juan Yang, Juan Jiang, Jian-Cheng Wang^*, Qiang Zhang. In vitro investigation of RGD-modified stabilized cationic liposomes as non-viral vehicle for siRNA delivery[J]. .

References

[1] Dorsett, Y.; Tuschl, T. Nat. Rev. Drug Discov. 2004, 3,318-329.
[2] Hannon, G.J.; Rossi J.J. Nature. 2004, 431, 371-378.
[3] Wu, H.; Hait W.N.; Yang J.M.; Cancer. Res. 2003, 63,1515-1519.
[4] Duan, Z.; Brakora, K.A.; Seiden, M.V.; Mol CancerTher. 2004, 3, 833-838.
[5] Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.;Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.;Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.;Lavine, G.; Pandey, R.K.; Racie, T.; Rajeev, K.G.; Rohl,I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.;Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H.P.Nature. 2004, 432, 173-178.
[6] Elmen, J.; Thonberg, H.; Ljungberg, K.; Frieden, M.;Westergaard, M.; Xu, Y.; Wahren, B.; Liang, Z.; Orum,H.; Koch, T.; Wahlestedt, C. Nucl. Acid. Res, 2005, 33,439-447.
[7] Chiu, Y.L.; Ali, A.; Chu, C.Y.; Cao, H.; Rana, T.M.Chem. Biol. 2004, 11, 1165-1175.
[8] Braasch, D.A.; Paroo, Z.; Constantinescu, A.; Ren, G.;Oz, O.K.; Mason, R.P.; Corey, D.R. Bioorg. Med. Chem.Lett. 2004, 14, 1139-1143.
[9] Zimmermann, T.S.; Lee, A.C.; Akinc, A.; Bramlage, B.;Bumcrot, D.; Fedoruk, M.N.; Harborth, J.; Heyes, J.A.;Jeffs, L.B.; John, M.; Judge, A.D.; Lam, K.; McClintock,K.; Nechev, L.V.; Palmer, L.R.; Racie, T.; Rohl, I.; Seiffert,S.; Shanmugam, S.; Sood, V.; Soutschek, J.; Toudjarska,I.; Wheat, A.J.; Yaworski, E.; Zedalis, W.; Koteliansky,V.; Manoharan, M.; Vornlocher, H.P.; MacLachlan,I. Nature. 2006, 441, 111-114.
[10] Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche,V.; Durieux, B.; Loffler, K.; Fechtner, M.; Rohl, T.;Fisch, G.; Dames, S.; Arnold, W.; Giese, K.; Klippel, A.Kaufmann, J. Gene Ther. 2006, 13, 1360-1370.[11] Li, S.D.; Chono, S.; Huang, L. Mol. Ther. 2008, 16,942-946.
[12] Temming, K.; Schiffelers, R.M.; Molema, G.; Kok, R.J.Drug Resist.Updat. 2005, 8, 381-402.
[13] Jain, R.K.; Duda, D.G. In: Davis, D.W.; Herbst, R.S.;Abbruzzese J.L. (Eds.), Antiangiogenic Cancer Therapy.Boca Raton: CRC Press, 2008, pp 43-90.
[14] Xiong, X.B.; Huang, Y.; Lu, W.L.; Zhang, X.; Zhang,H.; Nagai, T.; Zhang, Q. J.Controlled Release. 2005,107, 262-275.
[15] Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang,Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, P.V.;Woodle, M.C. Nucl. Acid.Res. 2004, 32, e149.
[16] Schiffelers, R.M.; Mixson, A.J.; Ansari, A.M.; Fens,M.H.; Tang, Q.; Zhou, Q.; Xu, J.; Molema, G.; Lu,P.Y.; Scaria, P.V.; Storm, G.; Woodle, M.C. J.Controlled Release. 2005, 109, 5-14.
[17] Gao, X.; Huang, L. Biochem. Biophys. Res. Commun.1991, 179, 280-285.
[18] Stierle, V.; Laigle, A.; Jolles, B. Biochem. Pharmacol.2005, 70, 1424-1430.
[19] Zelphati, O.; Nguyen, C.; Ferrari, M.; Felgner, J.; Tsai,Y.; Felgner, P.L. Gene Ther. 1998, 5, 1272-1282.
[20] Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche,V.; Fisch, G.; Dames, S.; Loffler, K.; Fechtner, M.Arnold, W.; Giese, K.; Klippel, A.; Kaufmann J. GeneTher. 2006, 13, 1222-1234.
[21] Li, W.; Szoka, F.C. Jr. Pharm. Res. 2007, 24, 438-449.
[22] Li, S.D.; Huang, L. Mol. Pharm. 2006, 3, 579-588.
[23] Yang, J.P.; Huang, L. Gene Ther. 1997, 4, 950-960.
[24] Dykxhoorn, D.M.; Lieberman, J. Cell. 2006, 126, 231-235.
[25] Xiong, X.B.; Huang, Y.; Lu W.L.; Zhang, X.; Zhang, H.;Nagai, T.; Zhang, Q. J. Pharm. Sci. 2005, 94, 1782-1793.
[26] Xiong, X.B.; Huang, Y.; Lu, W.L.; Zhang, H.; Zhang,X.; Zhang, Q. Pharm. Res. 2005, 22, 933-939.
[27] Chauhan, S.S.; Liang, X.J.; Su, A.W.; Pai-Panandiker,A. Shen, D.W.; Hanover, J.A.; Gottesman, M.M. Br. J.Cancer. 2003, 88, 1327-1334.
[28] Yan, W.W.; Sc, M. thesis. Peking University, 2003.
[29] Pedroso de Lima, M.C.; Simões S.; Pires, P.; Faneca, H.Düzgünes N. Adv. Drug Deliv. Rev. 2001, 47, 277-294.